Patient Support Programs From Drug Manufacturers During COVID-19


Patient Support Programs From Drug Manufacturers During COVID-19




In even the most normal of times, drug manufacturers play an important part in supporting patient access to medications through various programs that help cut out-of-pocket costs and provide education about their products. During this pandemic, these programs play an even more important role to ensure that patients do not struggle to continually receive and take their treatments.

The manufacturers below all have programs available for patients taking one of their products. To learn more about each product’s support program, click the link below to see what type of support you qualify for. During the coronavirus pandemic, many of these manufacturers are expanding these support programs to cover new patients who previously did not qualify. If you have checked before and were unable to receive any support, try checking again and see if there have been any changes to the program’s eligibility.

This page with be updated periodically with any statements issued by these companies as they manage the impact of this pandemic.

Bristol Myers Squibb (BMS)

In light of the Coronavirus pandemic, BMS has expanded its patient support program to help eligible unemployed patients in the US who have lost their health insurance due to COVID-19. This program offers access to BMS medications for FREE and is designed for patients with a current prescription for a BMS medication and who lost their job and health insurance due to the pandemic.

BMS has also expanded the program to cover non-US residents who are unable to travel to their home country to access their medications due to the pandemic.

For access to the expanded support program, please call 1-800-721-8909 or visit


Janssen CarePath offers two cost-support programs for commercially insured patients currently taking SIMPONI ARIA (golimumab).

The Janssen CarePath Treatment Administration Rebate Program provides support with patients’ out-of-pocket infusion administration costs. This program cuts patient costs to $0 with a maximum benefit of $2000. It is NOT available to patients who live in Massachusetts, Michigan, Minnesota, or Rhode Island and it is also NOT available to patients using Medicare, Medicaid, or other government-funded insurance plans. All other patients could qualify. For more information on this program, click here.

Additionally, the Janssen CarePath Savings Programs offers support for the patients’ out-of-pocket costs for their medication itself. Eligible patients would pay $5 per dose of their medication with a $20,000 maximum benefit. Janssen offers this program to patients who take SIMPONI ARIA, STELARA, REMICADE, OR SIMPONI. Like the Rebate program, it is NOT available to patients who use Medicare, Medicaid, or other government-funded insurance plans.

For more information on the Savings Program for SIMPONI ARIA, click here.

For more information on the Savings Program for STELARA, click here.

For more information of the Savings Program for REMICADE, click here.

For more information on the Savings Program for SIMPONI, click here.

And for additional support programs for other Janssen products, click here.

Horizon Therapeutics

On April 6th, Horizon began to offer support to patients, providers, and partners through a virtual portal until at least May 1st, 2020. To find the contact information for any of their patient support programs, click here and to see Horizon’s full statement about COVID-19, click here.

To see the update in Spanish, please click here.


On April 1st, Merck sent out a Dear Colleague letter detailing what they were doing in response to the coronavirus pandemic. The letter answered questions about what Merck is doing for clinical trials, COVID-19 research, supply chains, and philanthropy. To read the full letter, click here. Additional questions can be answered on Merck’s website by clicking here.


Sanofi has not had any disruption to manufacturing Kevzara and they continue to offer their patient support program through KenzaraConnect. Patients can access this program by clicking here.


In response to COVID-19, Pfizer has temporarily adapted some elements of the Pfizer Patient Assistance Program to accommodate the evolving needs of patients and ensure they get access to their medicines without interruption. To date, upon request, they have responded by increasing patient supply during the quarantine, where possible, approved telehealth prescribing, and more. If you or someone you know needs help accessing a physician-prescribed Pfizer medicine, please contact Pfizer RxPathways at 1-844-989-7284.

More answers to questions related to Pfizer’s response to COVID-19 can be found by clicking here.

People who are prescribed Pfizer Biosimilars may also contact Pfizer enCompass by clicking here.

Patients prescribed XELJANZ can find additional support by clicking here.

Patients who have medication questions about a Pfizer prescription should contact Pfizer Medical Information at (800) 438-1985. For information on specific products, patients and caregivers can click here.


In response to the COVID-19 pandemic, Sandoz released the attached statement on it’s promise to keep prices stable.

On March 20th, Sandoz released another statement detailing its donation of up to 130 million doses of Hydroxychloroquine in the effort to help fight the COVID-19 pandemic.

Boehringer Ingelheim (BI)

Boehringer Ingelheim has created two new places on their websites for patients to find out up-to-date information about COVID-19 and what BI is doing to fight it. Click here for information from BI focused on the US and click here for information from BI focused on international efforts.


Genentech has created a dedicated page on their website to be used as a COVID-19 resource during the pandemic that is constantly being updated. Click here to access that page and for any questions related to Genentech medicines and COVID-19, patients and their families should call the Genentech Patient Resource Center at 1-877-436-3683. For questions about help paying for Genentech medicine, patients and their families should click here to learn any options they may have.


Allergan has issued the attached statement with regards to migraine patients’ access to Botox treatments during this time of quarantine.


During the COVID-19 pandemic, AbbVie has updated their patient assistance and they are offering 100% relief to those that have temporarily lost their job due, and potentially their insurance, through this pandemic. For information on whether patient’s who take an AbbVie product qualify for patient assistance, please call the dedicated numbers below. 

  • For HUMIRA patients: 1(800) 4HUMIRA [1(800) 448-6472] 
  • For RINVOQ patients: 1(800) 2RINVOQ [1(800) 274-6867] 
  • For SKYRIZI patients: 1(866) SKYRIZI [1(866) 759-7494] 


Patients or providers can gather specific information on patient eligibility criteria for each program for Gilead treatments by calling the phone numbers below or clicking the accompanying links. 

  • Cayston Access Program®
    Phone: 1-877-722-9786

Media Contact: Jessica Daitch | Phone: 917-816-6712 | Email: [email protected]

Find us online:
CreakyJoints Español:
CreakyJoints Australia:
Global Healthy Living Foundation:
Facebook: &
Twitter: @GHLForg, @CreakyJoints, #CreakyChats
Instagram: @creaky_joints, @creakyjoints_aus, @creakyjoints_esp
TikTok: globalhealthylivingfnd

About Global Healthy Living Foundation
The Global Healthy Living Foundation is a 501(c)(3) nonprofit organization whose mission is to improve the quality of life for people with chronic illnesses (such as arthritis, osteoporosis, migraine, psoriasis, inflammatory bowel disease, and cardiovascular disease) by advocating for improved access to health care at the community, state, and federal levels, and amplifying education and awareness e!orts within its social media framework. GHLF is also a staunch advocate for vaccines. The Global Healthy Living Foundation is the parent organization of CreakyJoints®, the digital community for millions of arthritis patients and caregivers worldwide who seek education, support, activism, and patient-centered research through our ArthritisPower® ( Research Registry. In response to the COVID-19 pandemic, GHLF started a Patient Support Program, informed by a patient council made up of people living with a wide range of chronic illnesses, that now serves more than 30,000 people. Via CreakyJoints, GHLF also hosts PainSpot (, a digital risk-assessment tool for musculoskeletal conditions and injuries, and eRheum (, for telehealth and virtual-care support. Visit for more information.

Was this article helpful?
Back To Top